What is the present valuation and projected CAGR of the corneal endothelial dystrophy market?
The corneal endothelial dystrophy market size has grown strongly in recent years. It will grow from $170.96 billion in 2024 to $185.38 billion in 2025 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to growing healthcare expenditures, rise in the prevalence of such endothelial corneal dystrophy, growing aging population, increasing prevalence of eye diseases, and surge in prevalence of corneal disorders.
The corneal endothelial dystrophy market size is expected to see strong growth in the next few years. It will grow to $252.88 billion in 2029 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to rise in corneal blindness in emerging economies, increasing awareness about eye care, demand for corneal transplantation, rise in healthcare infrastructure, and increasing prevalence of chronic disorders. Major trends in the forecast period include advancements in regenerative therapies, advancement in medical technology, advancements in diagnostic techniques, technological advancements in ophthalmic lasers, and advanced technologies.
Get Your Free Sample of The Global Corneal Endothelial Dystrophy Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21158&type=smp
What key drivers have fueled the corneal endothelial dystrophy market’s development over the years?
The growing demand for corneal transplantation is expected to drive the growth of the corneal endothelial dystrophy market going forward. Corneal transplantation is a surgical procedure in which a damaged or diseased cornea is replaced with a healthy donor cornea to restore vision and improve eye health. The demand for corneal transplantations is due to the rising prevalence of corneal diseases, advancements in surgical techniques, and improved organ donation rates. Corneal endothelial dystrophy is treated with corneal transplantation, which replaces the damaged endothelium with healthy donor tissue to restore corneal clarity, reduce edema, and improve vision. For instance, in 2023, according to the Eye Bank Association of America, a US-based transplant association, domestic keratoplasty (a form of corneal transplantation) procedures increased by 2.7%, rising from 49,597 in 2022 to 50,925 in 2023. Therefore, the growing demand for corneal transplantation is driving the growth of the corneal endothelial dystrophy market.
What is the segmentation for the corneal endothelial dystrophy market?
The corneal endothelial dystrophy market covered in this report is segmented –
1) By Treatment: Phototherapeutic Keratectomy, Amniotic Membrane Transplants, Anterior Stromal Puncture, Conjunctival Flaps
2) By Disease Type: Congenital Hereditary Endothelial Dystrophy 1, Congenital Hereditary Endothelial Dystrophy 2, Posterior Polymorphous Corneal Dystrophy, Fuchs Endothelial Corneal Dystrophy
3) By Diagnosis: Cornea Examination And Grading, Corneal Tomography, Corneal Pachymetry, Corneal Cell Count
4) By End-User: Hospitals, Clinics, Other End Users
Subsegments:
1) By Phototherapeutic Keratectomy: Excimer Laser Therapy, Corneal Reshaping
2) By Amniotic Membrane Transplants: Fresh Amniotic Membrane Transplant, Cryopreserved Amniotic Membrane Transplant
3) By Anterior Stromal Puncture: Manual Technique, Laser-Assisted Technique
4) By Conjunctival Flaps: Partial Flap Technique, Full Flap Technique
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/corneal-endothelial-dystrophy-global-market-report
Who are the most influential companies in the corneal endothelial dystrophy market?
Major companies operating in the corneal endothelial dystrophy market are F. Hoffmann-La Roche AG, Abbvie (Allergan plc), Teva Pharmaceutical Industries Ltd, Fujifilm Holdings Corporation, Alcon Inc., Bausch Health+Lomb, Santen Pharmaceutical Co., Ltd., AGC Biologics Inc, Lumenis Ltd, Aurion Biotech Inc, Carl Zeiss Meditec AG, Keeler Limited, Kowa Company Ltd., ProQR Therapeutics N.V., Cellusion Inc., OptoTech GmbH, ActualEyes Inc., Arctic Vision Inc., Aurion Biotech LLC, Emmecell S.R.L
What are the top industry trends projected to impact the corneal endothelial dystrophy market?
Major companies operating in the corneal endothelial dystrophy market are focusing on developing innovative treatments, such as allogeneic cell therapy, to address unmet medical needs by offering innovative, minimally invasive treatment options that improve patient outcomes. Allogeneic cell therapy refers to using cells from a donor of the same species but genetically distinct to treat a recipient. For instance, in September 2024, Aurion Biotech Inc., a US-based clinical-stage biotech company, launched Vyznova (neltependocel) in Japan to treat bullous keratopathy, a corneal endothelial disease. Vyznova (neltependocel) is a cell therapy developed by Aurion Biotech to treat bullous keratopathy, which damages the corneal endothelial cells and causes vision problems. It is the first approved cell therapy for corneal endothelial disease and has been approved in Japan. Vyznova uses corneal endothelial cells grown in a lab, allowing up to 1,000 doses to be made from a single donor. This innovative treatment offers a less invasive alternative to corneal transplants, helping address the shortage of donor corneas and providing a new way to restore vision for patients with corneal diseases.
What are the major regional insights for the corneal endothelial dystrophy market, and which region holds the top position?
North America was the largest region in the corneal endothelial dystrophy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the corneal endothelial dystrophy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Corneal Endothelial Dystrophy Market Report 2025 Offer?
The corneal endothelial dystrophy market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Corneal endothelial dystrophy is a genetic eye disorder that affects the cornea’s endothelium (the inner layer of cells), leading to progressive loss of corneal clarity. The condition is characterized by the degeneration of the endothelial cells responsible for maintaining proper fluid balance within the cornea.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21158
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
